Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average) (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $91.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $91.3 million, up 5.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.3 million (up 5.67% YoY), and the FY2025 annual result was $89.3 million, up 4.99% from the prior year.
• Shares Outstanding (Weighted Average) improved to $91.3 million in Q1 2026 per GYRE's latest filing, from $89.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $91.3 million in Q1 2026 and troughed at $31.5 million in Q1 2022.
• A 5-year average of $67.4 million and a median of $83.3 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) increased 0.33% in 2022, then surged 123.36% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $63.6 million in 2022, then increased by 3.53% to $65.8 million in 2023, then grew by 29.26% to $85.1 million in 2024, then advanced by 4.99% to $89.3 million in 2025, then grew by 2.21% to $91.3 million in 2026.
• Business Quant data shows GYRE's Shares Outstanding (Weighted Average) at $91.3 million in Q1 2026, $89.3 million in Q4 2025, and $90.9 million in Q3 2025.